World How AstraZeneca's latest vaccine troubles could slow the global recovery
Here's who's eligible for COVID-19 vaccines in each state
The availability of COVID-19 vaccines is becoming more widespread, prompting states to increase the categories of residents eligible to get vaccinated.President Biden has directed states to make all adults eligible for a vaccine by May 1. More recently, he said he expects 90 percent of adults to be eligible for the vaccine by April 19.Every state has opened eligibility to residents age 65 or older, certain essential workers and residents 16 or older with certain high-risk medical conditions.Here's where each state and the District of Columbia stands on vaccine eligibility for other residents.AlabamaGov.
AstraZeneca's vaccine is key to ending the global economic slump caused by the coronavirus. But aby the drugmaker and new concerns over blood clots risk undermining public confidence in the shot and delaying the recovery.
European drug regulatorsbetween the Oxford-AstraZeneca Covid-19 shot and rare blood clots on Wednesday, but stopped short of recommending its use be limited. UK authorities recommended that people under 30 take alternative vaccines.
Canada pauses AstraZeneca vaccine for under 55
Ben Rhodes had a shot at Martin Truex Jr. on the final restart, but after missing a shift, he ended his day with a second-place finish.
It's the latest setback for AstraZeneca, which has faced criticism over its communication with the public and regulators, the design of its vaccine trials and severe production delays that have slowed the rollout of shots in Europe.
Authorities maintain that the benefits of the vaccine far outweigh the risks for most age groups. Yet shifting guidance and blood clot worries risk snarling distribution efforts in many countries. Germany suspended the use of the AstraZeneca vaccine last week in people under 60 years old, while Australia said Thursday it will not give it to people under the age of 50.
The safety questions could have even bigger implications for developing and middle-income countries, many of which are relying on the shot to unlock their economic comebacks because it's cheaper than other vaccines and can be stored more easily. Many are accessing it through Covax, a global vaccine-sharing program, which has secured more than half its supply from AstraZeneca as of March.
UK finds 30 blood clot cases after AstraZeneca jab
The cases identified by the medicines regulator were out of more than 18 million doses given.The Medicines and Healthcare products Regulatory Agency (MHRA) says the risk of having this type of clot is "very small".
Overall, orders for an estimated 2.4 billion doses of AstraZeneca's vaccine have been confirmed, according to the Duke Global Health Innovation Center. That's roughly 28% of the global total.
"There's a lot of uncertainty here," said Ben May, director of macro research at Oxford Economics. He said the AstraZeneca developments weren't enough to revise near-term growth forecasts, but that he would keep monitoring the situation closely.
The World Health Organization said in a statement Wednesday that "based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed."
AstraZeneca said that nearly 200 million people around the world have already received its vaccine, and that reviews by EU and UK regulators "reaffirmed the vaccine offers a high-level of protection against all severities of Covid-19 and that these benefits continue to far outweigh the risks."
U.K. Cites 7 Clot Deaths; U.S. Cases Trend Upward: Virus Update
The U.K. confirmed seven people had died from blood clots after receiving AstraZeneca Plc’s vaccine. More than 18 million doses have been administered in the country, and the regulator insists the shot is safe. Weekly U.S. infections hit their highest point since late February, even with vaccinations at record levels. France’s economy will rebound less than previously expected this year due to the latest four-week nationwide lockdown.The Philippines extended a lockdown in Manila and nearby provinces by at least a week as active coronavirus cases reached the highest in Southeast Asia.
A rough start
AstraZeneca received emergency use authorization from the United Kingdom in late December and the European Union one month later. Because the vaccine was less expensive and could be stored at higher temperatures than ones developed by Pfizer and Moderna, it was heralded as a breakthrough, particularly for less affluent countries that lack sophisticated logistics networks.
The company also generated lots of goodwill by pledging to supply its vaccine at no profit during the pandemic, and by partnering with the Serum Institute of India, which agreed to produce more than 1 billion doses for low and middle-income countries. AstraZeneca has already provided over 30 million doses to more than 58 countries through Covax.
However, a series of missteps generated a string of bad headlines for the Anglo-Swedish drugmaker.
The first issue cropped up in November, when the company faced questions about data from large-scale trials. Volunteers received different doses due to a manufacturing error, creating confusion about its actual effectiveness.
"More than a panic wind": the AstraZeneca vaccine shuddered in the north of France
in Boulogne-sur-Mer, Calais and Gravelines, the vaccination centers could not administer all their doses of the AstraZeneca vaccine . © Fred Tanneau / AFP A nurse vaccinates a healthy student with the AstraZeneca Covid-19 vaccine, on March 12, 2021 at the UBO (University of West Brittany) in Brest, in western France. The cases of thrombosis after receiving the AstraZeneca vaccine are very rare. The French Medicine Agency (ANSM) counts twelve, total, on several million injections.
AstraZeneca did not mention that a mistake caused the dosing discrepancy in its initial announcement, generating concerns about a lack of transparency.
"I hate to criticize fellow academics, or anyone for that matter, but releasing information like this is like asking us to try and read the tea leaves," Dr. Saad Omer, a vaccine specialist at the Yale School of Medicine, said at the time.
More stumbles followed. Germany's vaccine commission said in January that AstraZeneca's shots shouldn't be given to people older than 65, citing insufficient data for the age group. France also initially limited AstraZeneca vaccines to those under 65. Both countries changed course last month.
Jeffrey Lazarus, head of the health systems research group at the Barcelona Institute for Global Health, previously told CNN Business this was an "easily avoidable" issue tied to trial design.
Had the vaccine rollout been smooth, such stumbles may have been forgotten. But continued shortfalls in supply of the AstraZeneca shots in Europe, which is now mired in a third wave of coronavirus infections, havein the bloc. Leaders have imposed restrictions on vaccine exports.
"If we had received the 100% of AstraZeneca's vaccines that were contracted to us, the European Union would be at the same level today as Great Britain in terms of vaccines," European Commissioner Thierry Breton said in a recent interview with Le Parisien newspaper. "So I can say that the pocket of turbulence we have experienced is solely due to AstraZeneca's failure to deliver."
U.S. Bet Big on Covid Vaccine Manufacturer Even as Problems Mounted
San Diego State’s Klara Thormalm has been named the Mountain West Swimmer of the Year as voted on by the league’s coaches. Wyoming’s Melissa Mirafuentes was selected as the MW Diver of Year.
AstraZeneca's future role
The company also ran afoul of US regulators last month when it submitted trial data from the country. The US National Institute of Allergy and Infectious Diseases expressed concerns that the efficacy information submitted was "outdated." AstraZeneca quickly sent in revised data, but Dr. Anthony Fauci, the agency's director, called it "an unforced error."
Now, as fears about rare blood clots force governments around the world to reassess the risk-benefit analysis of providing shots to all age groups, the United States has indicated it does not need AstraZeneca's doses.
"We have enough very good vaccines," Fauci, who also serves as chief medical adviser to President Joe Biden, told CNN on Wednesday.
Not all countries will have that luxury, however. India, for example, is leaning heavily on AstraZeneca's shot as it tries to fight back against an.
Lazarus said Thursday that if wealthier nations decide they want to reduce their reliance on AstraZeneca, he hopes shots can be sent to other nations in need, since the data still indicates it's safe and effective.
"There are plenty of other countries that don't have other options because of the logistics ... and because of the cost," he said.
He does worry, however, that all the bad publicity could affect people's willingness to accept an AstraZeneca vaccine when it becomes available.
"This is definitely going to impact the reputation of the AstraZeneca vaccine," Lazarus said. "[It] will lead to lower uptake."
That could be bad news for the global economic recovery. This week, the International Monetary Fund upgraded its forecast for global growth this year to 6%. But that estimate depends in part on the pace of the vaccine rollout.
"Anything that might effectively reduce vaccine availability is obviously not good news," said May of Oxford Economics.
The vaccine "is still usable for the most vulnerable sections of the population," he noted. But coupled with supply shortages, new restrictions could complicate the recovery in countries where AstraZeneca's vaccine is central to pandemic exit strategies, May said.
Immigrant aid, lifeguard shortage, Frontier Days: News from around our 50 states .
How the COVID-19 pandemic is affecting every stateStart the day smarter. Get all the news you need in your inbox each morning.